934268-52-7

Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-Phenylbutylamine HCL is used as a chiral building block for the synthesis of various pharmaceutical drugs. Its unique properties make it a valuable component in the development of medications targeting the central nervous system.
Used in Central Nervous System Applications:
(R)-1-Phenylbutylamine HCL is used as a selective serotonin releasing agent for applications related to the central nervous system. Its stimulant and entactogen properties contribute to its potential use in the treatment of certain neurological and psychiatric conditions.
Used in Research and Development:
(R)-1-Phenylbutylamine HCL is utilized as a research compound to study its effects on the central nervous system and explore its potential in the development of new medications and therapies. (R)-1-PHENYLBUTYLAMINE HCL's properties make it a promising candidate for further investigation and application in the field of neuroscience.

Upstream product

• 108-86-1 bromobenzene 
• 2941-19-7 (R)-1-phenylbutylamine 
• 22135-49-5 (S)-1-phenylbutan-1-ol 
• 1315317-99-7 (S)-2,4,6-trimethyl-N-((S)-1-phenylbutyl)-benzenesulfinamide 
• 607729-51-1 (S)-N-2,4,6-trimethylbenzenesulfinyl benzaldehyde imine 
• 1218989-64-0 (S)-2-methyl-propane-2-sulfinic acid [(S)-1-phenyl-butyl]amide 
• 112342-79-7 n-butyrophenone oxime 
• 1034110-31-0 (R,S)-N-(tert-butyloxycarbonyl)-α-n-propylbenzylamine 

Downstream Products

• 3789-60-4 (S)-1-amino-1-phenylbutane 

Relevant academic research and scientific papers

APPLICATIONS OF N6-SUBSTITUTED ADENOSINE DERIVATIVE AND N6-SUBSTITUTED ADENINE DERIVATIVE TO CALMING, HYPNOSES, CONVULSION RESISTANCE, EPILEPTIC RESISTANCE, PARKINSON DISEASE RESISTANCE, AND DEMENTIA PREVENTION AND TREATMENT

PROBLEM TO BE SOLVED: To prepare analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. SOLUTION: The present invention relates to an N6-substituted adenosine derivative and an N6-substituted adenine derivative selected from the group consisting of specific compounds. The present invention also relates to a pharmaceutical composition at least comprising a therapeutically effective amount of the compounds and a pharmaceutically acceptable carrier. The invention further relates to the compounds used in preparation of analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. COPYRIGHT: (C)2016,JPO&INPIT

Reversal diastereoselectivity between the organomagnesium and organolithium reagents on Chiral N-tert-butylsulfinylaldimines for the preparation of chiral amines

The asymmetric synthesis of both the enantiomer of chiral amines from the single chiral source of N-tert-butylsulfinylaldimines (3) by simply changing the organometallic reagents through diastereoselective addition. An efficient enantioselective synthesis of chiral amines including (S)-3-methyl-1-(2- piperidin-1-yl-phenyl)butyl amine (6a), a key intermediate to prepare antidiabetic drug repaglinide (1), is reported.

N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

Synthesis and optimization of novel (3S,5R)-5-(2,2-dimethyl-5-oxo-4- phenylpiperazin-1-yl)piperidine-3-carboxamides as orally active renin inhibitors

We report synthesis and optimization of a series of (3S,5R)-5-(2,2- dimethyl-5-oxo-4-phenylpiperazin-1-yl)piperidine-3-carboxamides as renin inhibitors. Chemical modification of P1, P2 and P 3 portions led to a promising 3

N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

One-pot synthesis of chiral nonracemic amines

One-pot five-component reactions of oxathiazolidine-S-oxides with mesitylmagnesium bromide, lithium bis(trimethylsilyl)amide, aldehydes and Grignard reagents afford chiral nonracemic amines or sulfinamides in good yields and high stereoselectivities.

3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 1: Discovery and exploration of the carboxyamide side chain

A series of 3-(2-aminocarbonyl-4-phenoxymethylphenyl)propanoic acid analogs were synthesized and evaluated for their EP3 antagonist activity in the presence of additive serum albumin. Several compounds were biologically evaluated for their in vivo efficacy with respect to the PGE2-induced uterine contraction in pregnant rats as well as their pharmacokinetics. The discovery process of these potent and selective EP3 antagonists and their structure activity relationship are also presented.

Asymmetric reductive amination: Convenient access to enantioenriched alkyl-alkyl or aryl-alkyl substituted α-chiral primary amines

A two-step procedure for producing optically active, high value primary amines has been developed. The first and key step is the asymmetric reductive amination of a prochiral alkyl alkyl (acyclic or cyclic) or aryl alkyl (acyclic or cyclic) ketone with (R